Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have achieved promising effects in patients with non-small cell lung cancer (NSCLC). However, not all patients with NSCLC benefit from immunotherapy. There is an urgent need to explore biomarkers that could predict the survival outcomes and therapeutic efficacy in advanced NSCLC patients treated with immunotherapy. In this study, we aimed to assess the changes in peripheral blood lymphocyte subsets and their association with the therapeutic efficacy and clinical prognosis of advanced NSCLC patients treated with immunotherapy.

Methods

A total of 276 patients with advanced NSCLC were enrolled. Peripheral blood lymphocyte subsets including CD4⁺ T cells, CD8⁺ T cells, CD4⁺/CD8⁺ ratio, NK c

SUBMITTER: Yan Y 

PROVIDER: S-EPMC9052648 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature